Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $78.80 Average Target Price from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have received an average recommendation of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $78.80.

Several equities analysts recently commented on HALO shares. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a report on Monday, October 20th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $73.34 on Friday. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $79.50. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The stock has a market cap of $8.62 billion, a P/E ratio of 15.44, a PEG ratio of 0.32 and a beta of 0.94. The company’s 50-day simple moving average is $68.90 and its 200 day simple moving average is $68.27.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the business earned $1.27 earnings per share. The company’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, research analysts forecast that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised guidance and posted strong preliminary 2025 metrics — Halozyme updated preliminary 2025 revenue to $1.385–$1.40B and raised 2026 revenue guidance to $1.71–$1.81B; it also lifted royalty, adjusted EBITDA and non?GAAP EPS guidance, signaling stronger top?line and cash?flow outlooks. PR Newswire
• Positive Sentiment: Market reacted to the stronger preliminary results and raised outlook — coverage notes a near?term share uptick after management lifted 2026 guidance and preliminary 2025 results beat expectations. This supports momentum and re?rates HALO on growth expectations. Zacks
• Positive Sentiment: Acquisition of Surf Bio expands drug?delivery capabilities — Halozyme bought Surf Bio (deal up to $400M) to add a hyperconcentration technology that complements its ENHANZE platform, potentially expanding addressable markets for biologics delivery and future royalty streams. Contract Pharma
• Positive Sentiment: Analyst support — H.C. Wainwright reiterated a Buy and keeps a $90 price target, citing strategic and financial strength of the ENHANZE platform, which may sustain analyst/retail demand. InsiderMonkey
• Neutral Sentiment: Longer?term projections published — Management outlined sustained growth into the 2030s/2040s driven by ENHANZE and new technologies; important for long?term investors but less decisive for near?term moves. Benzinga
• Neutral Sentiment: Management call and filings available — Q4/2025 sales/trading call transcript and slides provide detail for modeling royalty cadence, margin assumptions and Surf Bio integration plans; useful for updating forecasts. Seeking Alpha
• Negative Sentiment: EPS guidance nuance — 2026 non?GAAP EPS was set at $7.75–$8.25 versus consensus ~ $7.86; while revenue/royalty guidance was raised, the EPS range overlaps but is not meaningfully above consensus, which could temper upside for EPS?sensitive investors. PR Newswire

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $50,721,994.47. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Cortney Caudill sold 4,263 shares of the firm’s stock in a transaction on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total value of $277,904.97. Following the completion of the sale, the chief operating officer owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. This trade represents a 25.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,661 shares of company stock valued at $3,139,257 in the last three months. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at about $385,000. Koa Wealth Management LLC grew its stake in shares of Halozyme Therapeutics by 7.5% during the fourth quarter. Koa Wealth Management LLC now owns 93,108 shares of the biopharmaceutical company’s stock valued at $6,266,000 after purchasing an additional 6,465 shares during the last quarter. Ashton Thomas Private Wealth LLC increased its holdings in shares of Halozyme Therapeutics by 3.7% in the fourth quarter. Ashton Thomas Private Wealth LLC now owns 9,586 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 343 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Halozyme Therapeutics by 4.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 18,736 shares of the biopharmaceutical company’s stock valued at $1,261,000 after purchasing an additional 727 shares in the last quarter. Finally, ST Germain D J Co. Inc. raised its position in Halozyme Therapeutics by 19.7% in the 4th quarter. ST Germain D J Co. Inc. now owns 2,628 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 432 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.